The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
about
Emerging treatment options for myelofibrosis: focus on pacritinibBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FRuxolitinib in the treatment of polycythemia vera: patient selection and special considerationsDiagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroHSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansMyeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.Chronic myeloproliferative neoplasms: a collaborative approach.Investigational Janus kinase inhibitors.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responsePhase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Therapeutic potential of JAK2 inhibitors.Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm.Treatment options for essential thrombocythemia and polycythemia vera.JAK2 inhibitors: what's the true therapeutic potential?Special issues in myeloproliferative neoplasms.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Myelofibrosis: an update on current pharmacotherapy and future directions.Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.Acute myeloid leukemia: advances in diagnosis and classification.Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.How we diagnose and treat essential thrombocythaemia.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Leukemic transformation in essential thrombocythemia.Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms.Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumNo association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.Very poor outcome of leukemic transformation in myelofibrosis: a single center experience with 13 patients.Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).Leukaemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms: are Asian patients different?Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
P2860
Q26745939-3F541820-1730-4E05-A51A-A6A2C158B31BQ26777265-FEBEB6AA-5DE8-4E94-A402-F94D4AF703EBQ26795666-799AD52F-B9F3-4D41-8EDE-0A352183EED2Q28078404-178259E4-FC94-41CC-ADB6-B064D2EA2CABQ30315531-CFB86CBC-2B14-497E-A969-056073B8925EQ34162151-51DE535B-5A0B-4000-9E8D-47F3FE9A3E69Q34474214-4DED3BCB-4D10-4451-92DC-4E3990A77131Q34549335-837A988E-4DFD-42C3-8860-E53668B1CE54Q34648724-ABF38794-6CAB-4AF0-A1DB-9BE2FE53560BQ34652224-98937436-5D4E-4EC3-B9E0-C0B38EE1C371Q35157388-995B0663-0536-427B-B6C9-B0A267416BB0Q35163764-A6404EB9-DCDB-4D3B-A35E-CB88FD8FB0A6Q35552421-D8796282-22B0-4295-8493-03BB4EAE45FAQ35988523-810F41E2-5F17-4C82-BE77-E399F1EB8A49Q37163487-9F301A4E-71E6-43A2-BA52-E6BF425284FBQ37361527-C377959B-D8F7-4FD8-84F3-6D90F4BA5AD8Q37555790-4191974E-EB70-4AD3-BF6E-999FFF176715Q37653313-43EDF3FA-94E2-4F03-9EA9-C22AB11A6ACAQ37686879-AD56807A-7B1E-4C94-9EB3-5EBDA12BE8FCQ37810107-4108D2F7-0A62-4A05-9EDA-C687528B1400Q37811430-01DA7FB9-7445-4CDD-AE3E-F4FAFD0ED23EQ37823434-3B778F7E-1D04-4684-B70E-DC17B5A1C0CAQ37968531-B8CC5525-2164-42A2-87BB-A533C7B4E685Q38018908-A9E6A3F5-1295-4A4A-9AD6-51EBC0004489Q38091447-DA914895-DD88-462A-B3BE-95D477422403Q38097735-73A3DCA5-3C3B-4BDC-AFE9-501A3B0C00A9Q38099426-C947C796-8158-4CEF-8B0F-69AB69782CFAQ38429716-83A1A948-A92A-40AC-BCA5-C06DC1B14752Q38606595-C15A92A1-1CA0-4893-8D57-CA1A9C21803BQ38683077-FB6FA7B9-4562-4D26-A11D-776DD6E08316Q38725723-F1C21622-DA4E-4834-A3EC-024CEE07CC4FQ38844669-39C88EC8-513A-406B-A596-F8E191FCD3B3Q39069487-BA0C6B3E-B2D2-4554-A589-59B5B6B76D74Q39813469-1A4B8833-EEFB-4263-BE43-4BBB22C85014Q42753989-C226F4CE-E872-4824-B543-268CE367EA1FQ43065879-9F1B61A1-55C5-42E2-A71E-ECD43F71472EQ44107175-E2F12E28-C046-4D99-8334-470B3C511613Q44380116-4BF0665F-AC29-481C-A198-27DCCF57816EQ44458761-AF10598C-0F89-4D6D-9AD0-D91DD45FD3BDQ48100617-9045AF3C-06C0-4AF8-93C2-9F26915EB9A8
P2860
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The natural history and treatm ...... myeloproliferative neoplasms.
@en
type
label
The natural history and treatm ...... myeloproliferative neoplasms.
@en
prefLabel
The natural history and treatm ...... myeloproliferative neoplasms.
@en
P2093
P2860
P1433
P1476
The natural history and treatm ...... myeloproliferative neoplasms.
@en
P2093
Carlos E Bueso-Ramos
Constantine S Tam
Deborah A Thomas
Jorge A Cortes
Richard E Champlin
Roberto M Nussenzveig
Sherry M Pierce
Stefan E Ciurea
Taghi Manshouri
Uday Popat
P2860
P304
P356
10.1182/BLOOD-2008-02-138230
P407
P577
2008-06-19T00:00:00Z